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correlation between the different variables and cardiac 
damage is ongoing. 
 
Poster: Clinical track: Breast  
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Purpose or Objective: To evaluate the rate of complications 
and the aesthetic outcome in previously irradiated patients 
who underwent mastectomy and subsequent prosthetic 
reconstruction in 2 times. 
 
Material and Methods: Eighty-three patients who underwent 
immediate postmastectomy reconstruction with tissue 
expander between January of 2003 and June of 2012 at the 
Campus Bio-Medico University Hospital in Rome were 
retrospectively divided into two groups: Group A (study 
group) included 30 patients with previous quadrantectomy 
and radiotherapy who underwent salvage mastectomy after 
local recurrence and Group B (control group) included 53 
patients submitted to primary radical mastectomy. Patients 
and disease characteristics were analysed and complications 
were correlated to treatment group. 
 
Results: The median follow-up time for the whole group was 
36 months (range= 12-144 months). Between group A and 
group B, there were no significant differences in terms of 
age, body mass index, comorbidities, pathological stage, 
treatments data (p=NS). In Group A 25/30 patients (83.33%) 
completed heterologous reconstruction. In 5 patients 
(16.67%) a conversion to combined or solely autologous 
reconstruction was needed. In Group B, 52/53 patients 
(98.11%) completed heterologous reconstruction. In 1 case 
(1.88%) the expander was removed due to infection and an 
autologous reconstruction was performed. Revision surgery 
was needed in 5 patients (9.4%). Autologous salvage 
reconstruction was more frequent for Group A patients 
(relative risk 10.4, p=0.02). The overall rate of complications 
was not different between the two groups (66.6% vs 58.5%; 
p=0.49) even if major complications (vast necrosis of 
mastectomy flaps with or without partial implant exposure, 
with or without implant removal, all III and IV-degree 
capsular contractures, either requiring or not requiring 
further surgery) were non significantly higher in the 
irradiated group (53.3% vs 32.0%; p= 0.07). However, 
analysing capsular contracture, a significantly higher risk of 
grade III-IV were recorded in Group A (40% vs 15%; relative 
risk 3.75, p=0.02). In Group A the median time from RT to 
reconstruction was 24 months (range= 9-192 months) and the 
incidence of major complications was not related to time 
from RT to reconstruction (p=0.313).  
 
Conclusion: Heterologus reconstruction after salvage 
mastectomy in previously irradiated patients, is still possible 
with satisfactory results. 
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Purpose or Objective: Germline polymorphisms in oxidative 
stress response genes have been postulated to be involved in 
the development of late normal tissue complications 
following radiotherapy. Despite the key role of mitochondria 
in the production of reactive oxygen species, the contribution 
of mitochondrial DNA variations to clinical radiosensitivity is 
still largely unknown. In the present study, we evaluated the 
association between mitochondrial DNA haplogroups and the 
risk of radiation-induced subcutaneous fibrosis after 
postoperative radiotherapy in breast cancer patients. 
 
Material and Methods: Subcutaneous fibrosis was scored 
according to the Late Effects of Normal Tissue-Subjective 
Objective Management Analytical (LENT-SOMA) scale in 286 
Italian breast cancer patients who received radiotherapy 
after breast conserving surgery. Eight mitochondrial DNA 
(mtDNA) SNPs that define the nine major haplogroups in the 
European population were determined by PCR–RFLP analysis 
on genomic DNA extracted from peripheral blood. 
 
Results: In a Kaplan-Meier analysis evaluated by the log-rank 
test, carriers of haplogroup H were found at lower risk of 
grade ³2 subcutaneous fibrosis (P=0.018). In the multivariate 
Cox regression analysis adjusted for clinical factors (BMI, 
breast diameter, adjuvant treatment, dose per fraction, 
radiation type and acute skin toxicity), the haplogroup H 
emerged as significant protective factor for moderate to 
severe radiation-induced fibrosis (HR: 0.50, 95% CI 0.27-0.92, 
P=0.027). 
 
Conclusion: Our results support a protective role of the 
mitochondrial haplogroup H in the development of radiation-
induced fibrosis in breast cancer patients. Further 
prospective studies with larger sample size and different 
populations are nevertheless warranted to corroborate the 
possible influence of mitochondrial haplogroups on late 
normal tissue radiosensitivity. 
 
PO-0674  
Factors influencing patient reported cosmetic outcome: 
results of the Young Boost Trial 
P. Brouwers
1MAASTRO clinic, Department of Radiation Oncology, 
Maastricht, The Netherlands 
1, E. Van Werkhoven2, J. Van Loon1, P. 
Poortmans3, H. Bartelink2, L. Boersma1 
2The Netherlands Cancer Institute, Department of Radiation 
Oncology, Amsterdam, The Netherlands 
3Radboud University Medical Center, Department of 
Radiation Oncology, Nijmegen, The Netherlands 
 
Purpose or Objective: The Young Boost trial (YBT), a 
multicenter RCT (NCT00212121), investigates whether a 
higher boost dose leads to a lower recurrence rate in young 
patients treated with breast conserving therapy. Cosmetic 
outcome is the secondary objective. The aim of the current 
analysis is to investigate the factors influencing the patients’ 
opinion about cosmesis.  
 
Material and Methods: From 2004-2011, 2421 breast cancer 
patients ≤ 50 yrs were included in The Netherlands, France, 
and Germany. All patients were treated with lumpectomy, 
followed by 50 Gy whole breast irradiation. Patients were 
randomized to receive a standard 16 Gy (n=1211) or a high 26 
Gy boost (n=1210) to the tumour bed. Cosmetic outcome data 
at 4 years of 807 patients were used for the current analysis 
according to the following two scoring systems:  
1. BCCT.core: Digital photographs were analyzed using a 
software program to extract an overall cosmetic score: 
excellent, good, fair or poor. This score is based on 
symmetry, skin color and scar visibility. The 7 features of 
symmetry in the BCCT.core program are: nipple position 
(pBRA), level of lower breast contour (pLBC), level of nipple 
(pUNR), distance from nipple to inframammary fold (pBCE), 
length of breast contour (pBCD), area of the breast (pBAD) 
and non-overlapping area between left and right breast 
(pBOD). 2. Patients’ score using a validated patient’s 
questionnaire about the breast appearance, including an 
overall score: very satisfied, satisfied, not dissatisfied, 
dissatisfied or very dissatisfied. First, we analyzed the 7 
features of BCCT.core in a proportional odds model, to 
ESTRO 35  2016                                                                                                                                                  S315 
________________________________________________________________________________ 
investigate which parameters were related to the patients‘ 
opinion about cosmesis. In addition, we analyzed whether 
firmness, presence of rib pain or quality of life (QoL) aspects 
(EORTC QLQ C-30 questionnaire) at 4 years were related to 
the patients’ opinion on cosmetic outcome.  
 
Results: Of the 7 BCCT.core parameters, pBCE and pBCD 
were significantly related to patients’ score at 4 years. 
Patients with any difference in firmness rated their cosmesis 
worse than patients without any difference, even when the 
objective score (i.e. BCCT.core) was similar. This effect was 
larger by increasing difference. Worse perception of cosmetic 
outcome was also independently related to lower global QoL, 
lower emotional functioning and higher scores in the 
depression scale. The presence of rib pain had no influence. 
 
Conclusion: The patients‘ opinion on cosmetic outcome was 
significantly related to objective parameters like distance 
from nipple to inframammary fold (pBCE) and length of 
breast contour (pBCD), but also to subjective factors, i.e. 
severity of firmness, depressive feelings, global QoL and 
emotional functioning. 
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Purpose or Objective: The primary endpoint of this phase II 
study was to determine the progression-free survival (PFS) of 
oligometastatic breast cancer patients treated with radical 
radiotherapy to all metastatic sites. 
 
Material and Methods: Patients affected by oligometastatic 
breast cancer were enrolled in this phase II trial. Inclusion 
criteria were the following: 1) histologically confirmed 
diagnosis of breast cancer, 2) 5 or fewer metastatic lesions, 
3) no brain metastases, 4) primary tumor controlled. 
Radiotherapeutic treatment was SBRT (30-45 Gy in 3 
fractions) or fractionated IMRT (40-60 Gy in 15-25 fractions). 
Primary endpoint was PFS; secondary endpoints were local-
control (LC), overall survival (OS), and toxicity, which was 
assessed using the CTCAE v4.0 scale. 
 
Results: The analysis was conducted on 37 patients. The 
median age was 55 years. Twenty-five (68%) had 
oligometastatic disease at diagnosis, and 12 (32%) had the 
oligometastatic status induced by systemic treatment. 
Sixteen (43%) patients had a single metastasis, and 21 (47%) 
had 2 or more lesions. Thirty-one (84%) patients were treated 
with SBRT and 6 (16%) with fractionated IMRT. With a median 
follow-up of 18 months, 1-year and 2-year PFS was 74% and 
44%, respectively. No differences was seen in PFS between 
patients with only 1 metastases vs. those with ≥2 metastases, 
or between patients treated with SBRT vs. fractionated IMRT. 
Only two patients experienced local failure. One of these two 
patients had an isolated local failure for a spinal lesion that 
was treated with a minimum dose of 17 Gy in 3 fractions 
(being the spinal cord constraint prior on the PTV coverage). 
Two-year LC was 96%. Two patients died of disease, and 2-
year OS was 96%. The proposed treatment was well 
tolerated; no Grade ≥3 toxicity was documented. Two 
patients experienced Grade 2 pain, 4 Grade 1 pain, and 2 
developed Grade 2 fatigue. 
 
Conclusion: Radical radiotherapy delivered to all the 
metastatic sites in oligometastatic breast cancer patients led 
to promising results in terms of local control and progression-
free survival. Treatment was well tolerated. The results of 
this study may motivate for conducting phase III trials. 
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Purpose or Objective: Previous studies have shown an 
increased risk of ischemic heart disease in breast cancer 
patients treated with radiotherapy (RT). It has recently been 
reported that the risk of major coronary events increases per 
gray of mean radiation dose delivered to the heart for 
patients undergoing either left- or right-sided breast RT. 
However, the anatomy of cardiovascular damage related to 
right-sided breast RT has not been well-described, 
specifically for radiation dose delivered to the right coronary 
artery (RCA). This may be of particular relevance for regional 
nodal irradiation that includes the internal mammary nodes 
(IMNs). In this prospective planning study, the impact of IMN 
irradiation on the RCA and organs at risk (OAR) in patients 
undergoing right-sided post-mastectomy RT (PMRT) was 
assessed. 
 
Material and Methods: CT simulation scans of 60 right-sided 
post-mastectomy patients were identified from an 
institutional database. In 30 cases, the IMNs were contoured 
from the 1st to 3rd intercostal space with a PTV of 5 mm. 
The RCA, heart, lungs and contralateral breast were 
delineated as OARs. A four-field modified wide tangent 
photon plan was created encompassing the chestwall, IMNs, 
supraclavicular fossa and axilla. For the remaining 30 
patients (control group), a four-field plan that excluded the 
IMNs was generated. All patients were planned to receive 50 
Gy in 25 fractions over 5 weeks. Doses were compared 
between the two groups utilizing the Mann-Whitney test to 
determine whether there was a statistically significant 
difference in dose to OARs between these groups. 
 
Results: In the group with IMN treatment, 95% of prescribed 
dose to the IMN PTV covered a median volume of 99% (range 
90-100). There was a significant increase in dose to the RCA 
in the IMN treated group compared to the control group. The 
maximum dose to the RCA (3.33 Gy vs 2.35 Gy, p<0.0001) and 
mean RCA dose (2.41 Gy vs 1.69 Gy, p<0.0001) were both 
increased. Similarly, the mean heart dose (MHD) was 
increased (1.3 Gy vs 1.09 Gy, p<0.022). Inclusion of the IMNs 
increased lung V20 (18 Gy vs 15 Gy, p<0.00021) and mean 
lung dose (9.1 Gy vs 8.09 Gy, p<0.00051). There was a 
significant increase in the volume of contralateral breast 
receiving 3 Gy in the group requiring IMN treatment (3.75 Gy 
vs 0 Gy, p<0.0001). 
 
Conclusion: Inclusion of the IMNs in patients undergoing 
PMRT significantly increases radiation dose to the RCA and 
MHD. An acceptable dose to the RCA has not been well-
established but should be as low as is reasonably achievable. 
The dose and clinical implications of radiation to the RCA 
needs further evaluation in prospective studies utilizing 
techniques to minimize cardiac exposure. 
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